The estimated Net Worth of Lisa Ricciardi is at least 2.23 千$ dollars as of 25 July 2017. Lisa Ricciardi owns over 9,600 units of ContraFect Corp stock worth over 2,225$ and over the last 11 years Lisa sold CFRX stock worth over 0$.
Lisa has made over 2 trades of the ContraFect Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently Lisa bought 9,600 units of CFRX stock worth 11,904$ on 25 July 2017.
The largest trade Lisa's ever made was buying 9,600 units of ContraFect Corp stock on 25 July 2017 worth over 11,904$. On average, Lisa trades about 1,444 units every 101 days since 2014. As of 25 July 2017 Lisa still owns at least 9,600 units of ContraFect Corp stock.
You can see the complete history of Lisa Ricciardi stock trades at the bottom of the page.
Lisa's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 340, DURHAM, NC, 27713.
Over the last 10 years, insiders at ContraFect Corp have traded over 2,523,392$ worth of ContraFect Corp stock and bought 525,578 units worth 426,359$ . The most active insiders traders include Sol J Barer、Roger Pomerantz、Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of 16,159$. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth 1,850$.
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
ContraFect Corp executives and other stock owners filed with the SEC include: